Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Cytometry Part B: Clinical Cytometry, Wiley, Vol. 94, No. 2 ( 2018-03), p. 342-353
    Abstract: Validated assays are essential to generate data with defined specificity, consistency, and reliability. Although the process of validation is required for applying immunoassays in the context of clinical studies, reports on systematic validation of in vitro T cell assays are scarce so far. We recently validated our HLA‐peptide multimer staining assay in a systematic manner so as to qualify the method for monitoring antigen‐specific T cell responses after immunotherapy. Methods Parameters of the assay, specificity, precision, linearity, sensitivity, and robustness were assessed systematically. Experiments were designed to address specifically each parameter and are detailed. Results Nonspecific multimer staining was below the acceptance limit of 0.02% multimer (+) CD8 (+) cells. The assay showed acceptable precision in all dimensions it was repeated (CV  〈  10%) and also demonstrated a linear detection ( R 2   〉  0.99) of antigen specific cells. Conclusions We succeeded in validating the HLA‐multimer staining assay in a systematic manner. Additionally, we propose a technical framework and recommendations that can be applied for validating other T cell assessment methods. © 2016 International Clinical Cytometry Society
    Type of Medium: Online Resource
    ISSN: 1552-4949 , 1552-4957
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 2180651-2
    SSG: 12
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Efficacy and Mechanism Evaluation, National Institute for Health and Care Research, Vol. 3, No. 3 ( 2016-04), p. 1-80
    Abstract: In the UK almost 7000 people are diagnosed with leukaemia each year, but despite continuing advances in diagnosis and treatment with new drugs, such as the tyrosine kinase inhibitors, the majority of these patients will eventually die from their disease. Until quite recently, the only treatment to offer the possibility of long-term disease-free survival was allogeneic stem cell transplantation. However, this carries a substantial risk of mortality and is available to only a minority of patients. Objectives The aim of the study was to test the hypothesis that molecular and clinical responses, induced by T lymphocytes (T cells), can be predicted by increases in the number of CD8+ (cluster of differentiation 8-positive) T cells specific for the vaccine-encoded T-cell epitopes. This project also aimed to build on the established programme of deoxyribonucleic acid (DNA) fusion-gene vaccination delivered by intramuscular injection, exploiting a unique experience with electroporation, to induce durable immune responses with the aim of controlling disease by precision attack of the tumour by CD8+ T cells. Method A non-randomised, open-label, single-dose-level Phase II clinical trial in two patient groups [chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML)] on stable doses of imatinib. Human leucocyte antigen A2-positive (HLA A2+) patients were vaccinated with two DNA vaccines: (1) p.DOM–WT1-37 (epitope sequence: VLDFAPPGA); and (2) p.DOM–WT1-126 (epitope sequence: RMFPNAPYL). The HLA A2-negative patients formed an unvaccinated control group. The sample size for the HLA A2+ group was originally determined following Simon’s optimal Phase II trial design (Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10 :1–10). This was changed to A’Hern’s single-stage design during the course of the trial (A’Hern RP. Sample size tables for single-stage phase II designs. Stat Med 2001; 20 :859–66), which was endorsed by the trial’s independent oversight committees. Results The study included 12 patients with CML who were vaccinated and nine patients with CML who were unvaccinated as the control group. Both the vaccines and the electroporation were safe, with no new or unexpected toxicities. The evaluation adverse events of special interest (heart, bone marrow, renal) did not reveal safety concerns. Two BCR – ABL (breakpoint cluster region–Abelson murine leukaemia viral oncogene homolog 1) responses were observed, both of which were defined as a major response, with one in each group. Two Wilms’ tumour antigen 1 ( WT1 ) molecular responses were observed in the vaccinated group and one was observed in the control group. At an immunological level, the vaccine performed as expected. Conclusions The study met its primary decision-making target with one major molecular response in BCR–ABL transcript levels. Overall, the data showed, in this clinical setting, the immunogenicity and safety of the vaccine. Limitations The study did not complete recruitment and there were multiple hurdles that contributed to this failure. This is disappointing given the robust induction immune responses against WT1 T-cell responses in 7 out of 10 evaluable patients. Future work Evaluation of the p.DOM–WT1 vaccines in AML remains attractive clinically, but it is unlikely to be feasible at this time. Combination of the DNA vaccine approach with strategies to expand T-cell responses with immunomodulatory antibodies is in development. Funding details This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership, and Bloodwise.
    Type of Medium: Online Resource
    ISSN: 2050-4365 , 2050-4373
    Language: English
    Publisher: National Institute for Health and Care Research
    Publication Date: 2016
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Immunity, Elsevier BV, Vol. 42, No. 4 ( 2015-04), p. 591-592
    Type of Medium: Online Resource
    ISSN: 1074-7613
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2015
    detail.hit.zdb_id: 2001966-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Inflammatory Bowel Diseases, Oxford University Press (OUP), Vol. 13, No. 5 ( 2007-05), p. 537-546
    Type of Medium: Online Resource
    ISSN: 1078-0998
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2007
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Journal for ImmunoTherapy of Cancer, BMJ, Vol. 8, No. 2 ( 2020-07), p. e000778-
    Abstract: The role of tumor-associated macrophages (TAMs) in determining the outcome between the antitumor effects of the adaptive immune system and the tumor’s anti-immunity stratagems, is controversial. Macrophages modulate their activities and phenotypes by integration of signals in the tumor microenvironment. Depending on how macrophages are activated, they may adopt so-called M1-like, antitumor or M2-like, protumor profiles. In many solid tumors, a dominance of M2-like macrophages is associated with poor outcomes but in some tumor types, strong M1-like profiles are linked to better outcomes. We aimed to investigate the interrelationship of these TAM populations to establish how they modulate the efficacy of the adaptive immune system in early lung cancer. Methods Macrophages from matched lung (non-tumor-associated macrophages (NTAMs)) and tumor samples (TAMs) from resected lung cancers were assessed by bulk and single-cell transcriptomic analysis. Protein expression of genes characteristic of M1-like (chemokine (C-X-C motif) ligand 9) or M2-like (matrix metallopeptidase 12) functions was confirmed by confocal microscopy. Immunohistochemistry related the distribution of TAM transcriptomic signatures to density of CD8 + tissue-resident memory T cells (T RM ) in tumors and survival data from an independent cohort of 393 patients with lung cancer. Results TAMs have significantly different transcriptomic profiles from NTAMs with 〉 1000 differentially expressed genes. TAMs displayed a strong M2-like signature with no significant variation between patients. However, single-cell RNA-sequencing supported by immuno-stained cells revealed that additionally, in 25% of patients the M2-like TAMs also co-expressed a strong/hot M1-like signature (M1 hot ). Importantly, there was a strong association between the density of M1 hot TAMs and T RM cells in tumors that was in turn linked to better survival. Our data suggest a mechanism by which M1 hot TAMs may recruit T RM cells via CXCL9 expression and sustain them by making available more of the essential fatty acids on which T RM depend. Conclusions We showed that in early lung cancer, expression of M1-like and M2-like gene signatures are not mutually exclusive since the same TAMs can simultaneously display both gene-expression profiles. The presence of M1 hot TAMs was associated with a strong T RM tumor-infiltrate and better outcomes. Thus, therapeutic approaches to re-program TAMs to an M1 hot phenotype are likely to augment the adaptive antitumor responses.
    Type of Medium: Online Resource
    ISSN: 2051-1426
    Language: English
    Publisher: BMJ
    Publication Date: 2020
    detail.hit.zdb_id: 2719863-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Lung Cancer, Elsevier BV, Vol. 178 ( 2023-04), p. S69-S70
    Type of Medium: Online Resource
    ISSN: 0169-5002
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2023
    detail.hit.zdb_id: 2025812-4
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: Gastroenterology, Elsevier BV, Vol. 138, No. 4 ( 2010-04), p. 1536-1545
    Type of Medium: Online Resource
    ISSN: 0016-5085
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2010
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 1265-1265
    Abstract: Abstract 1265 The number of survivors who have undergone high-dose chemotherapy (HDT) with autologous progenitor cell rescue for malignant lymphoma is increasing. Data on long-term immunological reconstitution is limited, particularly for lymphocyte populations that are now more readily enumerated. Despite consensus guidelines, routine primary revaccination of this patient population has not been universally adopted. Methods From the Wessex Blood and Bone Marrow Transplant Registry, 130 patients (pts.) with malignant lymphoma, who had undergone HDT, and were known to be in an ongoing continuous remission for at least 3 years were identified and invited to participate with the aim of quantifying lymphocyte subsets and serological memory. Thirty-seven pts., median age 52 years (range 30–71) consented to study participation; their histologies comprised: diffuse large B-cell lymphoma, 32%; Hodgkin's disease, 27%; follicular lymphoma, 27%; other lymphomas, 14%. The median follow-up from the time of HDT to study entry was 10.6 years (range 3.0–20.2). All, except 4 pts., had received peripheral blood derived progenitor cells, which had been purged in 2 pts. An age matched population (median 56 years) of 14 healthy individuals (predominantly patient spouses) served as controls. Lymphocyte subsets in peripheral blood were assessed using multicolour flow cytometric analysis with a 16 antibody panel. Serum antibody levels to measles, mumps, rubella, HiB, tetanus and pneumococcus were determined by ELISA. Results There was no significant difference in T, B and NK-cell populations between long-term follow-up pts. and controls, however even at median follow-up of 10 years there were persisting altered CD4+/CD8+ ratios with a reduced proportion of CD4+ cells in pts. compared to controls (median CD4+ 43% vs. 63% respectively; P 〈 0.001). Naïve CD4+ cells were profoundly reduced in patients (P 〈 0.001) yet effector memory and central memory CD4+ cells were higher in the pts. (P 〈 0.001 and P=0.009 respectively).The effector memory RA population (intermediate between naïve and effector T-cells) were found in similar proportions between pts. and controls. Within the CD8+ population, the naïve population was reduced (P 〈 0.001) with a corresponding increase in CD8+ memory cells in pts (p 〈 0.001) however there was no difference in the level of central and effector memory CD8+ cells between pts. and controls. CD4+ T-cell numbers positively correlated with time form transplant, showing a continuous linear relationship. There were no significant differences in the proportion of memory and naïve B-cells between pts. and controls. Similarly there was no difference in marginal zone-like, class switch subtyes and mature plasmablasts proportions between the two groups. Uptake of revaccination following HDT was sporadic. Despite only 15 pts. (and only 1 pt receiving full course) being revaccinated, all patients demonstrated tetanus antibody levels above the minimal protective level. In two pts. who had received only a single dose of tetanus vaccine had antibody levels only just above the minimum. No pts. had been revaccinated against measles, mumps or rubella: 58%, 43% and 23% of pts respectively were below the equivocal serological level for immunity. No pt. had received pre HDT HiB vaccination and only 1 post HDT; 11% were below the minimal protective level. Four pts. had been vaccination against pneumococcus pre HDT and 13 pts. post: In 33% pts. antibody levels were below the minimum protective level. Conclusions Even at a median of 10 years following curative HDT, defects in lymphocyte subsets persist. The sustained reduction in naïve T-cell subsets, likely as a result of thymic incapacity, resulted in a peripheral T-cell population with a restricted TCR repertoire and the potential for impaired responses to novel antigenic stimuli many years after HDT. Other lymphocyte lineages however were able to fully reconstitute. Lack of serologically determined immunity was common, and the risk of incomplete vaccination scheduling demonstrated. In line with consensus statements, pts. following HDT should undergo full course revaccination or at least have assessment of their serological memory quantified to minimise the risk of infectious morbidity. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2010
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 22, No. 19 ( 2016-10-01), p. 4827-4836
    Abstract: Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin. Experimental Design: Twenty-seven patients with CEA-expressing carcinomas were recruited: 15 patients with measurable disease (arm-I) and 12 patients without radiological evidence of disease (arm-II). Six intramuscular vaccinations of naked DNA (1 mg/dose) were administered up to week 12. Clinical and immunologic follow-up was up to week 64 or clinical/radiological disease. Results: DOM-specific immune responses demonstrated successful vaccine delivery. All patients without measurable disease compared with 60% with advanced disease responded immunologically, while 58% and 20% expanded anti-CAP-1 CD8+ T cells, respectively. CAP-1–specific T cells were only detectable in the blood postvaccination but could also be identified in previously resected cancer tissue. The gastrointestinal adverse event diarrhea was reported by 48% of patients and linked to more frequent decreases in CEA (P & lt; 0.001) and improved global immunologic responses [anti-DOM responses of greater magnitude (P & lt; 0.001), frequency (P = 0.004), and duration] compared with patients without diarrhea. In advanced disease patients, decreases in CEA were associated with better overall survival (HR = 0.14, P = 0.017). CAP-1 peptide was detectable on MHC class I of normal bowel mucosa and primary colorectal cancer tissue by mass spectrometry, offering a mechanistic explanation for diarrhea through CD8+ T-cell attack. Conclusions: Our data suggest that DNA vaccination is able to overcome peripheral tolerance in normal and tumor tissue and warrants testing in combination studies, for example, by vaccinating in parallel to treatment with an anti-PD1 antibody. Clin Cancer Res; 22(19); 4827–36. ©2016 AACR.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2006
    In:  Respiratory Research Vol. 7, No. 1 ( 2006-12)
    In: Respiratory Research, Springer Science and Business Media LLC, Vol. 7, No. 1 ( 2006-12)
    Abstract: Fibroblasts are implicated in sub-epithelial fibrosis in remodeled asthmatic airways and contribute to airway inflammation by releasing cytokines and other mediators. Fibroblast activity is influenced by members of the leukotriene family of bronchoconstrictor and inflammatory mediators, but it is not known whether human bronchial fibroblasts can synthesize leukotrienes. Methods The expression of leukotriene biosynthetic enzymes and receptors was investigated in primary fibroblasts from the bronchi of normal and asthmatic adult subjects using RT-PCR, Western blotting, immunocytochemistry and flow cytometry. Results These techniques revealed that human bronchial fibroblasts from both subject groups constitutively express 5-lipoxygenase, its activating protein FLAP, the terminal enzymes leukotriene A 4 hydrolase and leukotriene C 4 synthase, and receptors for leukotriene B 4 (BLT1) and cysteinyl-leukotrienes (CysLT 1 ). Human bronchial fibroblasts generated immunoreactive leukotriene B 4 and cysteinyl-leukotrienes spontaneously and in increased amounts after calcium-dependent activation. Flow cytometry showed that human bronchial fibroblasts transformed to a myofibroblast-like phenotype by culture with transforming growth factor-β 1 expressed 320–400% more immunofluorescence for leukotriene C 4 synthase and CysLT 1 receptors, with 60–80% reductions in leukotriene A 4 hydrolase and BLT1 receptors. Conclusion These results indicate that human bronchial fibroblasts may not only respond to exogenous leukotrienes but also generate leukotrienes implicated in narrowing, inflammation and remodeling of the asthmatic airway.
    Type of Medium: Online Resource
    ISSN: 1465-993X
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2006
    detail.hit.zdb_id: 2041675-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages